25 XP   0   0   10

Walvax BioTech
Buy, Hold or Sell?

Let's analyse Walvax together

PenkeI guess you are interested in Walvax BioTech. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Walvax BioTech. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Walvax BioTech

I send you an email if I find something interesting about Walvax BioTech.

Quick analysis of Walvax (30 sec.)










What can you expect buying and holding a share of Walvax? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
97.5%

What is your share worth?

Current worth
¥7.09
Expected worth in 1 year
¥7.34
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
¥0.26
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
¥13.99
Expected price per share
¥0 - ¥19.16
How sure are you?
50%

1. Valuation of Walvax (5 min.)




Live pricePrice per Share (EOD)

¥13.99

Intrinsic Value Per Share

¥5.23 - ¥6.31

Total Value Per Share

¥12.32 - ¥13.40

2. Growth of Walvax (5 min.)




Is Walvax growing?

Current yearPrevious yearGrowGrow %
How rich?$1.5b$1.4b$97m6.2%

How much money is Walvax making?

Current yearPrevious yearGrowGrow %
Making money$14.4m$25.1m-$10.6m-73.7%
Net Profit Margin9.4%12.7%--

How much money comes from the company's main activities?

3. Financial Health of Walvax (5 min.)




What can you expect buying and holding a share of Walvax? (5 min.)

Welcome investor! Walvax's management wants to use your money to grow the business. In return you get a share of Walvax.

What can you expect buying and holding a share of Walvax?

First you should know what it really means to hold a share of Walvax. And how you can make/lose money.

Speculation

The Price per Share of Walvax is ¥13.99. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Walvax.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Walvax, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥7.09. Based on the TTM, the Book Value Change Per Share is ¥0.06 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Walvax.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.01-0.1%0.010.1%0.020.1%0.010.1%0.010.1%
Usd Book Value Change Per Share-0.02-0.1%0.010.1%0.020.2%0.030.2%0.020.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-0.1%0.010.1%0.020.2%0.030.2%0.020.1%
Usd Price Per Share3.25-3.73-6.24-5.54-4.54-
Price to Earnings Ratio-70.51-36.00-209.67-180.77-163.41-
Price-to-Total Gains Ratio-185.05-128.44-910.53-299.63-188.77-
Price to Book Ratio3.32-3.81-6.79-7.89-10.05-
Price-to-Total Gains Ratio-185.05-128.44-910.53-299.63-188.77-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.933418
Number of shares517
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.03
Usd Total Gains Per Share0.010.03
Gains per Quarter (517 shares)4.7314.21
Gains per Year (517 shares)18.9356.84
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1118925547
2236285109104
3354477164161
4472669218218
54908511273275
6510810414327332
7612612316382389
8714414218437446
9816216120491503
10918018023546560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%25.02.013.062.5%38.02.014.070.4%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%29.011.00.072.5%42.012.00.077.8%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%19.00.01.095.0%39.00.01.097.5%52.00.02.096.3%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%31.09.00.077.5%44.010.00.081.5%

Fundamentals of Walvax

About Walvax BioTech

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

Fundamental data was last updated by Penke on 2024-04-16 12:33:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Walvax BioTech.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Walvax earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -14.0% means that ¥-0.14 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Walvax BioTech:

  • The MRQ is -14.0%. The company is making a huge loss. -2
  • The TTM is 9.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-14.0%TTM9.4%-23.5%
TTM9.4%YOY12.7%-3.3%
TTM9.4%5Y13.6%-4.2%
5Y13.6%10Y25.0%-11.4%
1.1.2. Return on Assets

Shows how efficient Walvax is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.9% Return on Assets means that Walvax generated ¥-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Walvax BioTech:

  • The MRQ is -0.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.9%TTM0.7%-1.5%
TTM0.7%YOY1.2%-0.5%
TTM0.7%5Y1.2%-0.5%
5Y1.2%10Y1.2%0.0%
1.1.3. Return on Equity

Shows how efficient Walvax is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.4% Return on Equity means Walvax generated ¥-0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Walvax BioTech:

  • The MRQ is -1.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 1.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-1.4%TTM1.1%-2.5%
TTM1.1%YOY2.0%-0.9%
TTM1.1%5Y1.9%-0.8%
5Y1.9%10Y2.0%-0.1%

1.2. Operating Efficiency of Walvax BioTech.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Walvax is operating .

  • Measures how much profit Walvax makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Walvax BioTech:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM14.1%-14.1%
TTM14.1%YOY26.4%-12.3%
TTM14.1%5Y22.0%-7.8%
5Y22.0%10Y11.8%+10.2%
1.2.2. Operating Ratio

Measures how efficient Walvax is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.99 means that the operating costs are ¥0.99 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Walvax BioTech:

  • The MRQ is 0.991. The company is less efficient in keeping operating costs low.
  • The TTM is 0.909. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.991TTM0.909+0.081
TTM0.909YOY0.862+0.048
TTM0.9095Y0.935-0.026
5Y0.93510Y0.753+0.183

1.3. Liquidity of Walvax BioTech.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Walvax is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.73 means the company has ¥2.73 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Walvax BioTech:

  • The MRQ is 2.726. The company is able to pay all its short-term debts. +1
  • The TTM is 2.760. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.726TTM2.760-0.034
TTM2.760YOY2.540+0.220
TTM2.7605Y2.916-0.156
5Y2.91610Y1.667+1.249
1.3.2. Quick Ratio

Measures if Walvax is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.97 means the company can pay off ¥0.97 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Walvax BioTech:

  • The MRQ is 0.968. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.108. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.968TTM1.108-0.140
TTM1.108YOY1.096+0.012
TTM1.1085Y1.027+0.081
5Y1.02710Y0.862+0.165

1.4. Solvency of Walvax BioTech.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Walvax assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Walvax to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.27 means that Walvax assets are financed with 26.9% credit (debt) and the remaining percentage (100% - 26.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Walvax BioTech:

  • The MRQ is 0.269. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.267. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.269TTM0.267+0.002
TTM0.267YOY0.275-0.009
TTM0.2675Y0.232+0.035
5Y0.23210Y0.337-0.105
1.4.2. Debt to Equity Ratio

Measures if Walvax is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 44.9% means that company has ¥0.45 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Walvax BioTech:

  • The MRQ is 0.449. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.442. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.449TTM0.442+0.007
TTM0.442YOY0.458-0.017
TTM0.4425Y0.363+0.078
5Y0.36310Y0.694-0.330

2. Market Valuation of Walvax BioTech

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Walvax generates.

  • Above 15 is considered overpriced but always compare Walvax to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -70.51 means the investor is paying ¥-70.51 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Walvax BioTech:

  • The EOD is -41.957. Based on the earnings, the company is expensive. -2
  • The MRQ is -70.509. Based on the earnings, the company is expensive. -2
  • The TTM is 35.996. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-41.957MRQ-70.509+28.551
MRQ-70.509TTM35.996-106.505
TTM35.996YOY209.672-173.676
TTM35.9965Y180.768-144.772
5Y180.76810Y163.406+17.363
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Walvax BioTech:

  • The EOD is 115.374. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 193.884. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -97.825. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD115.374MRQ193.884-78.510
MRQ193.884TTM-97.825+291.709
TTM-97.825YOY219.374-317.199
TTM-97.8255Y6.738-104.563
5Y6.73810Y-6.382+13.120
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Walvax is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Walvax BioTech:

  • The EOD is 1.973. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.316. Based on the equity, the company is fair priced.
  • The TTM is 3.810. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.973MRQ3.316-1.343
MRQ3.316TTM3.810-0.494
TTM3.810YOY6.795-2.985
TTM3.8105Y7.885-4.076
5Y7.88510Y10.045-2.160
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Walvax BioTech compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1280.063-303%0.154-183%0.191-167%0.132-197%
Book Value Per Share--7.0907.1010%6.664+6%5.405+31%3.795+87%
Current Ratio--2.7262.760-1%2.540+7%2.916-7%1.667+64%
Debt To Asset Ratio--0.2690.267+1%0.275-2%0.232+16%0.337-20%
Debt To Equity Ratio--0.4490.442+2%0.458-2%0.363+23%0.694-35%
Dividend Per Share--0.0010.003-66%0.008-86%0.008-87%0.018-94%
Eps---0.0830.065-228%0.113-174%0.085-198%0.068-223%
Free Cash Flow Per Share--0.0300.029+4%0.017+77%-0.021+170%-0.024+178%
Free Cash Flow To Equity Per Share--0.0300.029+4%0.032-5%0.032-7%0.037-19%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.675+48%
Intrinsic Value_10Y_max--6.310--------
Intrinsic Value_10Y_min--5.229--------
Intrinsic Value_1Y_max--0.074--------
Intrinsic Value_1Y_min--0.072--------
Intrinsic Value_3Y_max--0.648--------
Intrinsic Value_3Y_min--0.610--------
Intrinsic Value_5Y_max--1.734--------
Intrinsic Value_5Y_min--1.573--------
Market Cap22486826723.840-68%37788798876.16043394432056.960-13%72551761347.200-48%64416962916.224-41%52785350415.190-28%
Net Profit Margin---0.1400.094-249%0.127-210%0.136-203%0.250-156%
Operating Margin---0.141-100%0.264-100%0.220-100%0.118-100%
Operating Ratio--0.9910.909+9%0.862+15%0.935+6%0.753+32%
Pb Ratio1.973-68%3.3163.810-13%6.795-51%7.885-58%10.045-67%
Pe Ratio-41.957+40%-70.50935.996-296%209.672-134%180.768-139%163.406-143%
Price Per Share13.990-68%23.51026.998-13%45.138-48%40.077-41%32.840-28%
Price To Free Cash Flow Ratio115.374-68%193.884-97.825+150%219.374-12%6.738+2778%-6.382+103%
Price To Total Gains Ratio-110.114+40%-185.045128.439-244%910.534-120%299.634-162%188.772-198%
Quick Ratio--0.9681.108-13%1.096-12%1.027-6%0.862+12%
Return On Assets---0.0090.007-228%0.012-171%0.012-170%0.012-170%
Return On Equity---0.0140.011-229%0.020-171%0.019-176%0.020-171%
Total Gains Per Share---0.1270.066-292%0.162-178%0.199-164%0.149-185%
Usd Book Value--1574838755.0361577340960.1600%1480246884.671+6%1200578025.372+31%843034483.024+87%
Usd Book Value Change Per Share---0.0180.009-303%0.021-183%0.026-167%0.018-197%
Usd Book Value Per Share--0.9800.9810%0.921+6%0.747+31%0.524+87%
Usd Dividend Per Share--0.0000.000-66%0.001-86%0.001-87%0.002-94%
Usd Eps---0.0120.009-228%0.016-174%0.012-198%0.009-223%
Usd Free Cash Flow--6733949.7256504148.092+4%3811351.815+77%-4715278.352+170%-3007422.533+145%
Usd Free Cash Flow Per Share--0.0040.004+4%0.002+77%-0.003+170%-0.003+178%
Usd Free Cash Flow To Equity Per Share--0.0040.004+4%0.004-5%0.004-7%0.005-19%
Usd Market Cap3107679453.235-68%5222412004.6855997110510.272-13%10026653418.183-48%8902424275.022-41%7294935427.379-28%
Usd Price Per Share1.933-68%3.2493.731-13%6.238-48%5.539-41%4.538-28%
Usd Profit---18516899.09914489931.797-228%25174926.923-174%18801773.124-198%15092468.416-223%
Usd Revenue--132081604.324142130833.904-7%175736681.491-25%115557934.758+14%71202439.202+86%
Usd Total Gains Per Share---0.0180.009-292%0.022-178%0.027-164%0.021-185%
 EOD+4 -4MRQTTM+8 -27YOY+13 -225Y+10 -2510Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of Walvax BioTech based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-41.957
Price to Book Ratio (EOD)Between0-11.973
Net Profit Margin (MRQ)Greater than0-0.140
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.968
Current Ratio (MRQ)Greater than12.726
Debt to Asset Ratio (MRQ)Less than10.269
Debt to Equity Ratio (MRQ)Less than10.449
Return on Equity (MRQ)Greater than0.15-0.014
Return on Assets (MRQ)Greater than0.05-0.009
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Walvax BioTech based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.743
Ma 20Greater thanMa 5015.261
Ma 50Greater thanMa 10016.760
Ma 100Greater thanMa 20019.401
OpenGreater thanClose14.190
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  264,664-53,932210,732206,560417,292-271,095146,197-321,442-175,245
Minority Interest  -52,26425,950-26,313-54,683-80,99644,453-36,54488,46251,918
Net Income  197,259-25,268171,991111,258283,249-185,11298,137-232,123-133,986
Net Income from Continuing Operations  249,522-51,218198,304165,941364,245-229,565134,680-320,585-185,904



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets15,588,869
Total Liabilities4,193,509
Total Stockholder Equity9,349,276
 As reported
Total Liabilities 4,193,509
Total Stockholder Equity+ 9,349,276
Total Assets = 15,588,869

Assets

Total Assets15,588,869
Total Current Assets8,733,170
Long-term Assets6,855,699
Total Current Assets
Cash And Cash Equivalents 4,364,535
Net Receivables 3,100,608
Inventory 1,034,637
Other Current Assets 53,755
Total Current Assets  (as reported)8,733,170
Total Current Assets  (calculated)8,553,536
+/- 179,635
Long-term Assets
Property Plant Equipment 3,768,350
Goodwill 33,658
Intangible Assets 1,485,543
Long-term Assets Other 307,589
Long-term Assets  (as reported)6,855,699
Long-term Assets  (calculated)5,595,140
+/- 1,260,558

Liabilities & Shareholders' Equity

Total Current Liabilities3,203,907
Long-term Liabilities989,603
Total Stockholder Equity9,349,276
Total Current Liabilities
Short Long Term Debt 320,271
Accounts payable 1,805,081
Other Current Liabilities 766,241
Total Current Liabilities  (as reported)3,203,907
Total Current Liabilities  (calculated)2,891,593
+/- 312,314
Long-term Liabilities
Long term Debt 434,896
Capital Lease Obligations Min Short Term Debt20,595
Long-term Liabilities Other 42,076
Long-term Liabilities  (as reported)989,603
Long-term Liabilities  (calculated)497,566
+/- 492,036
Total Stockholder Equity
Retained Earnings 2,902,836
Total Stockholder Equity (as reported)9,349,276
Total Stockholder Equity (calculated)2,902,836
+/- 6,446,440
Other
Capital Stock1,607,348
Common Stock Shares Outstanding 1,607,348
Net Invested Capital 10,104,443
Net Working Capital 5,529,264
Property Plant and Equipment Gross 3,768,350



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302009-12-312008-12-312007-12-31
> Total Assets 
217,515
301,898
386,120
619,140
678,407
2,986,420
2,808,220
2,883,849
2,895,417
3,007,058
2,978,582
3,048,946
3,458,199
4,450,265
4,457,349
4,548,698
5,715,230
6,135,837
6,488,736
6,249,731
6,076,907
5,967,716
5,825,904
6,314,876
6,630,281
6,257,841
6,954,902
6,863,229
6,655,719
6,324,014
5,945,703
5,693,694
5,720,233
5,875,971
6,045,877
6,061,338
6,937,661
7,237,021
6,969,687
7,023,526
7,059,193
7,017,725
6,914,393
7,195,702
8,557,817
9,638,289
10,290,568
10,969,153
12,496,732
13,674,114
14,008,442
14,978,623
14,843,448
15,327,991
15,434,647
15,650,334
15,591,154
15,588,869
15,588,86915,591,15415,650,33415,434,64715,327,99114,843,44814,978,62314,008,44213,674,11412,496,73210,969,15310,290,5689,638,2898,557,8177,195,7026,914,3937,017,7257,059,1937,023,5266,969,6877,237,0216,937,6616,061,3386,045,8775,875,9715,720,2335,693,6945,945,7036,324,0146,655,7196,863,2296,954,9026,257,8416,630,2816,314,8765,825,9045,967,7166,076,9076,249,7316,488,7366,135,8375,715,2304,548,6984,457,3494,450,2653,458,1993,048,9462,978,5823,007,0582,895,4172,883,8492,808,2202,986,420678,407619,140386,120301,898217,515
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,572,365
3,353,587
4,138,968
3,740,859
3,726,379
3,649,663
3,443,720
3,294,869
3,268,905
4,117,102
4,780,256
5,421,697
5,606,599
6,827,324
7,680,287
7,979,898
8,667,636
8,486,487
8,948,463
8,875,468
8,996,269
8,790,013
8,733,170
8,733,1708,790,0138,996,2698,875,4688,948,4638,486,4878,667,6367,979,8987,680,2876,827,3245,606,5995,421,6974,780,2564,117,1023,268,9053,294,8693,443,7203,649,6633,726,3793,740,8594,138,9683,353,5872,572,36500000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,367,109
2,115,418
2,484,306
2,351,921
2,265,069
2,160,068
2,381,235
2,129,947
1,946,413
2,002,621
1,961,580
2,317,122
2,222,196
2,510,757
3,443,388
3,775,103
3,749,772
3,624,461
3,873,475
3,815,244
3,906,337
4,086,662
4,364,535
4,364,5354,086,6623,906,3373,815,2443,873,4753,624,4613,749,7723,775,1033,443,3882,510,7572,222,1962,317,1221,961,5802,002,6211,946,4132,129,9472,381,2352,160,0682,265,0692,351,9212,484,3062,115,4181,367,10900000000000000000000000000000000000
       Net Receivables 
60,213
117,622
100,079
137,699
175,686
221,308
254,051
300,405
356,262
369,484
358,627
438,978
756,745
657,692
738,659
854,589
1,067,274
961,990
887,320
892,018
880,822
1,430,992
1,514,220
1,488,148
1,356,860
1,096,092
1,174,784
851,951
814,769
953,170
1,152,734
1,155,156
1,193,734
804,405
1,003,103
951,846
925,887
1,381,271
403,468
499,034
512,480
731,170
748,344
856,366
1,648,873
2,308,347
2,354,513
2,638,971
3,342,361
3,255,372
3,128,437
3,863,211
3,790,655
3,956,788
3,862,767
3,890,347
3,381,360
3,100,608
3,100,6083,381,3603,890,3473,862,7673,956,7883,790,6553,863,2113,128,4373,255,3723,342,3612,638,9712,354,5132,308,3471,648,873856,366748,344731,170512,480499,034403,4681,381,271925,887951,8461,003,103804,4051,193,7341,155,1561,152,734953,170814,769851,9511,174,7841,096,0921,356,8601,488,1481,514,2201,430,992880,822892,018887,320961,9901,067,274854,589738,659657,692756,745438,978358,627369,484356,262300,405254,051221,308175,686137,699100,079117,62260,213
       Other Current Assets 
6,333
1,254
31,784
21,847
31,744
8,461
21,628
22,978
72,308
71,021
73,268
47,644
111,970
109,885
190,422
216,551
180,863
129,887
137,964
106,894
98,410
49,838
44,084
56,573
95,295
65,467
90,927
92,249
139,212
500,599
47,784
39,451
38,757
20,564
25,961
44,491
68,654
37,107
225
241
1,232
18,266
21,476
53,887
20,571
26,769
177,720
119,542
156,624
107,936
157,720
118,889
107,144
122,385
116,494
57,548
41,830
53,755
53,75541,83057,548116,494122,385107,144118,889157,720107,936156,624119,542177,72026,76920,57153,88721,47618,2661,23224122537,10768,65444,49125,96120,56438,75739,45147,784500,599139,21292,24990,92765,46795,29556,57344,08449,83898,410106,894137,964129,887180,863216,551190,422109,885111,97047,64473,26871,02172,30822,97821,6288,46131,74421,84731,7841,2546,333
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,228,828
3,297,147
3,409,530
3,574,004
3,619,524
3,926,797
4,440,716
4,858,034
4,868,871
5,362,554
5,669,408
5,993,827
6,028,545
6,310,987
6,356,960
6,379,528
6,559,179
6,654,065
6,801,141
6,855,699
6,855,6996,801,1416,654,0656,559,1796,379,5286,356,9606,310,9876,028,5455,993,8275,669,4085,362,5544,868,8714,858,0344,440,7163,926,7973,619,5243,574,0043,409,5303,297,1473,228,82800000000000000000000000000000000000000
       Property Plant Equipment 
92,487
102,256
102,678
299,982
276,688
359,998
347,374
403,258
385,373
461,039
476,125
604,174
650,914
902,130
915,254
1,007,010
1,177,779
1,276,121
1,328,470
1,395,205
1,391,808
1,286,692
1,278,296
1,294,479
1,300,695
1,395,746
1,395,590
1,392,979
1,403,287
1,361,265
1,385,209
1,408,484
1,401,911
1,524,662
1,333,915
1,333,551
1,342,096
1,300,471
1,309,304
1,309,198
1,323,400
1,388,538
1,414,883
1,468,289
1,483,878
1,590,038
1,636,374
1,824,874
2,213,316
2,603,809
2,729,311
2,946,461
3,083,274
3,160,741
3,306,090
3,404,151
3,551,899
3,768,350
3,768,3503,551,8993,404,1513,306,0903,160,7413,083,2742,946,4612,729,3112,603,8092,213,3161,824,8741,636,3741,590,0381,483,8781,468,2891,414,8831,388,5381,323,4001,309,1981,309,3041,300,4711,342,0961,333,5511,333,9151,524,6621,401,9111,408,4841,385,2091,361,2651,403,2871,392,9791,395,5901,395,7461,300,6951,294,4791,278,2961,286,6921,391,8081,395,2051,328,4701,276,1211,177,7791,007,010915,254902,130650,914604,174476,125461,039385,373403,258347,374359,998276,688299,982102,678102,25692,487
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
945,991
945,991
945,991
689,494
689,494
950,721
950,721
469,575
469,575
469,575
469,575
107,348
107,348
107,348
107,348
106,819
106,819
106,819
106,819
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,658
33,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,65833,658106,819106,819106,819106,819107,348107,348107,348107,348469,575469,575469,575469,575950,721950,721689,494689,494945,991945,991945,991000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
335,253
390,291
751,558
325,103
848,199
849,155
862,271
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000862,271849,155848,199325,103751,558390,291335,25300000000000000000000000000000000000
       Intangible Assets 
20,389
22,867
35,693
2,848
36,883
2,663
39,732
2,807
40,862
2,718
51,740
2,470
65,467
837,935
1,152,389
819,664
2,089,048
900,662
1,873,921
1,860,432
1,846,910
855,064
850,527
1,153,975
1,147,976
718,461
711,669
704,182
697,095
262,894
260,808
302,436
300,954
270,603
250,359
139,087
134,635
145,077
844,220
861,441
914,718
1,002,884
1,020,414
1,037,634
1,096,182
1,150,049
1,173,448
1,282,242
1,414,801
1,445,742
1,446,292
1,459,587
1,450,372
1,432,511
1,452,920
1,461,087
1,470,473
1,485,543
1,485,5431,470,4731,461,0871,452,9201,432,5111,450,3721,459,5871,446,2921,445,7421,414,8011,282,2421,173,4481,150,0491,096,1821,037,6341,020,4141,002,884914,718861,441844,220145,077134,635139,087250,359270,603300,954302,436260,808262,894697,095704,182711,669718,4611,147,9761,153,975850,527855,0641,846,9101,860,4321,873,921900,6622,089,048819,6641,152,389837,93565,4672,47051,7402,71840,8622,80739,7322,66336,8832,84835,69322,86720,389
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
633,339
649,672
153,174
147,523
150,564
154,522
1,637,033
292,855
196,938
205,083
134,728
206,439
201,629
229,933
293,034
262,043
270,105
287,658
327,735
307,589
307,589327,735287,658270,105262,043293,034229,933201,629206,439134,728205,083196,938292,8551,637,033154,522150,564147,523153,174649,672633,33900000000000000000000000000000000000000
> Total Liabilities 
199,859
203,542
211,433
387,891
401,659
435,516
237,348
249,100
254,655
293,616
241,779
272,706
586,033
1,280,702
1,271,704
1,357,764
2,417,523
3,197,373
3,396,907
3,190,195
3,115,981
2,755,736
2,671,017
3,106,181
2,970,945
3,234,105
3,982,093
4,029,078
3,906,499
2,800,376
2,457,389
2,222,295
2,248,533
2,318,481
1,810,888
1,745,529
1,924,679
1,981,264
1,643,297
1,481,452
1,448,222
1,351,762
1,289,041
1,156,543
1,747,221
1,790,411
1,875,419
2,162,980
2,937,704
3,675,316
3,653,264
4,238,571
4,084,639
4,338,415
4,243,993
4,183,750
3,989,890
4,193,509
4,193,5093,989,8904,183,7504,243,9934,338,4154,084,6394,238,5713,653,2643,675,3162,937,7042,162,9801,875,4191,790,4111,747,2211,156,5431,289,0411,351,7621,448,2221,481,4521,643,2971,981,2641,924,6791,745,5291,810,8882,318,4812,248,5332,222,2952,457,3892,800,3763,906,4994,029,0783,982,0933,234,1052,970,9453,106,1812,671,0172,755,7363,115,9813,190,1953,396,9073,197,3732,417,5231,357,7641,271,7041,280,702586,033272,706241,779293,616254,655249,100237,348435,516401,659387,891211,433203,542199,859
   > Total Current Liabilities 
183,800
191,408
104,169
269,945
295,632
331,088
157,139
168,909
173,344
268,697
215,642
249,292
561,591
1,019,683
1,016,286
1,099,603
2,076,200
1,878,322
1,944,013
1,733,457
1,644,971
1,415,408
1,276,984
1,678,667
1,444,082
2,187,429
2,638,098
3,178,955
3,058,038
1,981,207
1,781,849
1,514,065
1,556,748
1,475,467
989,707
925,200
1,162,195
1,535,813
1,378,348
1,213,954
1,194,045
1,088,465
1,027,008
896,665
1,381,628
1,421,968
1,496,806
1,773,631
2,473,534
3,235,399
3,096,630
3,501,220
3,320,170
3,508,791
3,337,105
3,263,990
3,032,085
3,203,907
3,203,9073,032,0853,263,9903,337,1053,508,7913,320,1703,501,2203,096,6303,235,3992,473,5341,773,6311,496,8061,421,9681,381,628896,6651,027,0081,088,4651,194,0451,213,9541,378,3481,535,8131,162,195925,200989,7071,475,4671,556,7481,514,0651,781,8491,981,2073,058,0383,178,9552,638,0982,187,4291,444,0821,678,6671,276,9841,415,4081,644,9711,733,4571,944,0131,878,3222,076,2001,099,6031,016,2861,019,683561,591249,292215,642268,697173,344168,909157,139331,088295,632269,945104,169191,408183,800
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
20,000
120,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000120,00020,00030,00000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
20,000
120,000
0
0
40,000
40,000
40,000
160,000
190,000
212,000
310,000
290,000
230,000
168,098
97,182
50,000
130,007
100,089
320,271
320,271100,089130,00750,00097,182168,098230,000290,000310,000212,000190,000160,00040,00040,00040,00000120,00020,00030,00000000000000000000000000000000000000000
       Accounts payable 
58,757
36,968
12,546
74,228
61,793
60,769
58,375
49,667
37,169
49,102
51,056
43,724
56,700
120,964
135,301
156,448
255,262
165,357
163,030
193,021
196,086
161,246
187,608
226,712
257,189
237,002
242,717
209,241
182,841
151,912
143,623
207,811
219,371
213,445
205,251
215,381
244,239
251,795
240,897
255,459
257,602
276,740
305,278
302,285
343,977
607,792
610,002
673,645
944,745
1,255,947
1,285,676
1,272,787
1,390,883
1,836,299
2,036,752
2,053,425
1,888,444
1,805,081
1,805,0811,888,4442,053,4252,036,7521,836,2991,390,8831,272,7871,285,6761,255,947944,745673,645610,002607,792343,977302,285305,278276,740257,602255,459240,897251,795244,239215,381205,251213,445219,371207,811143,623151,912182,841209,241242,717237,002257,189226,712187,608161,246196,086193,021163,030165,357255,262156,448135,301120,96456,70043,72451,05649,10237,16949,66758,37560,76961,79374,22812,54636,96858,757
       Other Current Liabilities 
73,043
91,440
65,623
79,717
84,839
116,319
98,764
119,242
136,175
166,310
131,301
152,283
144,891
359,219
310,985
223,155
624,638
545,465
543,483
367,436
368,885
218,163
239,376
586,956
426,893
587,122
1,064,076
1,266,520
1,319,198
1,136,185
941,191
1,068,253
1,093,377
1,018,021
604,456
478,292
693,732
978,430
319,947
369,337
368,707
520,647
715,931
297,730
989,692
692,086
719,351
867,352
1,293,304
909,125
1,501,574
929,499
1,721,434
1,191,617
1,199,557
346,998
838,901
766,241
766,241838,901346,9981,199,5571,191,6171,721,434929,4991,501,574909,1251,293,304867,352719,351692,086989,692297,730715,931520,647368,707369,337319,947978,430693,732478,292604,4561,018,0211,093,3771,068,253941,1911,136,1851,319,1981,266,5201,064,076587,122426,893586,956239,376218,163368,885367,436543,483545,465624,638223,155310,985359,219144,891152,283131,301166,310136,175119,24298,764116,31984,83979,71765,62391,44073,043
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
264,948
267,498
254,177
263,296
262,033
259,878
365,593
368,443
378,613
389,349
464,170
439,917
556,634
737,352
764,469
829,624
906,888
919,759
957,805
989,603
989,603957,805919,759906,888829,624764,469737,352556,634439,917464,170389,349378,613368,443365,593259,878262,033263,296254,177267,498264,94800000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-30,000
-20,000
-120,000
0
0
0
0
0
511
2,275
1,669
1,065
561
13,777
15,393
27,738
30,331
26,551
16,990
20,595
20,59516,99026,55130,33127,73815,39313,7775611,0651,6692,27551100000-120,000-20,000-30,00000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
42,076
42,076000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,364,779
1,422,467
689,885
711,843
760,471
791,506
883,922
775,945
801,681
830,490
890,004
920,397
965,589
989,176
1,021,625
1,042,850
387,630
422,947
0
341,434
374,100
0
0
00374,100341,4340422,947387,6301,042,8501,021,625989,176965,589920,397890,004830,490801,681775,945883,922791,506760,471711,843689,8851,422,4671,364,77900000000000000000000000000000000000
> Total Stockholder Equity
17,656
98,356
174,688
231,250
276,748
2,550,904
2,570,872
2,634,749
2,640,762
2,713,441
2,736,803
2,776,240
2,872,166
2,954,135
2,979,993
2,985,460
2,926,637
2,742,562
2,691,194
2,671,701
2,583,616
2,882,906
2,834,646
2,793,527
2,880,173
2,284,596
2,242,541
2,155,591
2,083,882
3,207,253
3,170,186
3,156,469
3,160,171
3,027,283
3,357,679
3,403,752
3,684,027
4,574,026
4,631,471
4,773,709
4,825,097
4,865,163
4,833,703
5,083,797
5,776,293
6,544,755
7,058,043
7,392,263
8,107,198
8,484,232
8,620,495
8,956,352
8,898,801
9,083,857
9,258,560
9,453,479
9,551,616
9,349,276
9,349,2769,551,6169,453,4799,258,5609,083,8578,898,8018,956,3528,620,4958,484,2328,107,1987,392,2637,058,0436,544,7555,776,2935,083,7974,833,7034,865,1634,825,0974,773,7094,631,4714,574,0263,684,0273,403,7523,357,6793,027,2833,160,1713,156,4693,170,1863,207,2532,083,8822,155,5912,242,5412,284,5962,880,1732,793,5272,834,6462,882,9062,583,6162,671,7012,691,1942,742,5622,926,6372,985,4602,979,9932,954,1352,872,1662,776,2402,736,8032,713,4412,640,7622,634,7492,570,8722,550,904276,748231,250174,68898,35617,656
   Common Stock
11,260
16,965
75,000
75,000
75,000
100,000
100,000
150,000
150,000
150,000
150,000
180,000
182,232
182,232
182,232
182,232
180,000
180,000
180,000
234,000
234,000
234,000
234,000
468,000
468,000
1,404,000
1,404,000
1,404,000
1,404,000
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,537,437
1,543,452
1,546,237
1,563,694
1,566,187
1,591,158
1,601,345
1,601,572
1,601,977
1,605,253
0
1,607,347
1,607,348
0
0
001,607,3481,607,34701,605,2531,601,9771,601,5721,601,3451,591,1581,566,1871,563,6941,546,2371,543,4521,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,537,4371,404,0001,404,0001,404,0001,404,000468,000468,000234,000234,000234,000234,000180,000180,000180,000182,232182,232182,232182,232180,000150,000150,000150,000150,000100,000100,00075,00075,00075,00016,96511,260
   Retained Earnings 
6,396
41,096
97,061
153,623
199,122
251,478
271,446
328,009
334,022
396,193
419,555
458,991
506,572
568,525
594,383
599,850
559,674
563,909
552,786
533,293
445,208
744,497
696,238
665,672
621,123
0
0
0
0
0
0
0
0
0
0
-501,617
-483,656
471,428
468,590
468,669
504,102
573,191
555,073
634,682
977,797
1,545,508
1,577,667
1,786,396
1,831,570
1,894,947
1,933,567
2,272,714
2,383,098
2,580,356
2,752,462
3,019,718
3,036,823
2,902,836
2,902,8363,036,8233,019,7182,752,4622,580,3562,383,0982,272,7141,933,5671,894,9471,831,5701,786,3961,577,6671,545,508977,797634,682555,073573,191504,102468,669468,590471,428-483,656-501,6170000000000621,123665,672696,238744,497445,208533,293552,786563,909559,674599,850594,383568,525506,572458,991419,555396,193334,022328,009271,446251,478199,122153,62397,06141,0966,396
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196,333
0
0
0
0
0
0
0
182,736
190,875
190,875
190,875
190,875
216,325
216,325
216,325
216,325
0
217,175
217,175
0
0
00217,175217,1750216,325216,325216,325216,325190,875190,875190,875190,875182,7360000000196,333000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue4,113,772
Cost of Revenue-597,556
Gross Profit3,516,2163,516,216
 
Operating Income (+$)
Gross Profit3,516,216
Operating Expense-3,091,176
Operating Income1,022,596425,040
 
Operating Expense (+$)
Research Development776,425
Selling General Administrative1,615,980
Selling And Marketing Expenses0
Operating Expense3,091,1762,392,405
 
Net Interest Income (+$)
Interest Income74,233
Interest Expense-5,949
Other Finance Cost-349
Net Interest Income67,934
 
Pretax Income (+$)
Operating Income1,022,596
Net Interest Income67,934
Other Non-Operating Income Expenses0
Income Before Tax (EBT)598,9761,022,596
EBIT - interestExpense = -5,949
419,390
425,339
Interest Expense5,949
Earnings Before Interest and Taxes (EBIT)0604,925
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax598,976
Tax Provision-87,651
Net Income From Continuing Ops511,325511,325
Net Income419,390
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-67,934
 

Technical Analysis of Walvax
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Walvax. The general trend of Walvax is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Walvax's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Walvax BioTech.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.48 < 17.13 < 19.16.

The bearish price targets are: .

Tweet this
Walvax BioTech Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Walvax BioTech. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Walvax BioTech Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Walvax BioTech. The current macd is -0.92346918.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Walvax price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Walvax. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Walvax price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Walvax BioTech Daily Moving Average Convergence/Divergence (MACD) ChartWalvax BioTech Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Walvax BioTech. The current adx is 34.22.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Walvax shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Walvax BioTech Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Walvax BioTech. The current sar is 14.47.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Walvax BioTech Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Walvax BioTech. The current rsi is 30.74. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Walvax BioTech Daily Relative Strength Index (RSI) ChartWalvax BioTech Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Walvax BioTech. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Walvax price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Walvax BioTech Daily Stochastic Oscillator ChartWalvax BioTech Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Walvax BioTech. The current cci is -105.28233151.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Walvax BioTech Daily Commodity Channel Index (CCI) ChartWalvax BioTech Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Walvax BioTech. The current cmo is -39.85243011.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Walvax BioTech Daily Chande Momentum Oscillator (CMO) ChartWalvax BioTech Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Walvax BioTech. The current willr is -86.23481781.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Walvax BioTech Daily Williams %R ChartWalvax BioTech Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Walvax BioTech.

Walvax BioTech Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Walvax BioTech. The current atr is 0.55289037.

Walvax BioTech Daily Average True Range (ATR) ChartWalvax BioTech Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Walvax BioTech. The current obv is -533,901,364.

Walvax BioTech Daily On-Balance Volume (OBV) ChartWalvax BioTech Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Walvax BioTech. The current mfi is 32.47.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Walvax BioTech Daily Money Flow Index (MFI) ChartWalvax BioTech Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Walvax BioTech.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Walvax BioTech Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Walvax BioTech based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.743
Ma 20Greater thanMa 5015.261
Ma 50Greater thanMa 10016.760
Ma 100Greater thanMa 20019.401
OpenGreater thanClose14.190
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Walvax with someone you think should read this too:
  • Are you bullish or bearish on Walvax? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Walvax? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Walvax BioTech

I send you an email if I find something interesting about Walvax BioTech.


Comments

How you think about this?

Leave a comment

Stay informed about Walvax BioTech.

Receive notifications about Walvax BioTech in your mailbox!